Michael Thiele

Chief Scientific Officer OncoOne

Seminars

Wednesday 12th November 2025
Introducing a Tumour Agnostic Pre-Targeted Radiotherapeutic Platform to Target Tumour Associated Macrophages
11:30 am
  •  Pretargeting to increase therapeutic windows in RLTs
  • OncoOne’s Pretarg-it® platform
  • Data from preclinical tumor models and outlook
Michael Thiele, Chief Scientific Officer, OncoOne